HENDERSON REBECCA M 4

4 · IDEXX LABORATORIES INC /DE · Filed May 15, 2020

Form 4

Period: 2020-05-13

Director

Transactions

Exercise/Conversion
Common Stock
2020-05-13$64.69/sh+5,974$386,458→ 20,670 total
Exercise/Conversion
Non-Qualified Stock Option (right-to-buy)
2020-05-13−5,974→ 0 total
Exercise: $64.69Exp: 2024-05-06→ Common Stock (5,974 underlying)
Sale
Common Stock
2020-05-13$286.66/sh−5,974$1,712,487→ 14,696 total
Exercise/Conversion
Common Stock
2020-05-13$63.95/sh+7,422$474,637→ 22,118 total
Sale
Common Stock
2020-05-13$286.66/sh−7,422$2,127,565→ 14,696 total
Exercise/Conversion
Non-Qualified Stock Option (right-to-buy)
2020-05-13−7,422→ 300 total
Exercise: $63.95Exp: 2025-05-05→ Common Stock (7,422 underlying)

Footnotes (3)

[F1]Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 2,987 shares on May 7, 2015, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
[F2]Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 3,861 shares on May 6, 2016, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
[F3]Not spplicable.

Documents

1 file